Study of Gemcitabine, Irinotecan & Panitumumab in Patients With Advanced &

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05497531` - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	N/A
Recruiting	`NCT05678218` - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Recruiting	`NCT06010862` - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors	Phase 1
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Recruiting	`NCT05179486` - Molecular Epidemiology of Biliary Tree Cancers
Suspended	`NCT05124743` - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated	`NCT04304781` - Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer	Phase 1
Completed	`NCT03150615` - Enteral Nutrition After Pancreaticoduodenectomy	N/A
Completed	`NCT01912053` - Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma	Phase 2
Recruiting	`NCT01439698` - Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry	N/A
Terminated	`NCT01434459` - Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin	Phase 1
Completed	`NCT01206049` - Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations	Phase 2
Recruiting	`NCT00973713` - Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol	Phase 2
Terminated	`NCT00975039` - Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma	Phase 2
Completed	`NCT00779454` - Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma	Phase 2
Terminated	`NCT04066491` - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC	Phase 2/Phase 3
Recruiting	`NCT04340986` - Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
Active, not recruiting	`NCT04526106` - REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03603834` - Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma	Phase 2
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2

NCT number	NCT00948935
Study type	Interventional
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Completed
Phase	Phase 2
Start date	April 2009
Completion date	September 26, 2014

Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms